

December 26, 2008

AnGes MG, Inc.

Promotion of the Program Adopted by the Special District for
Development of Advanced Medical Care (Super Special District)

- GenomIdea Conducts Evaluations for the Formulation and
Manufacture of the Active Pharmaceutical Ingredient -

AnGes MG, Inc. is pleased to announce that its subsidiary, GenomIdea Inc. ("GenomIdea"), has carried out research and development activities that include evaluations for the formulation and manufacture of the active pharmaceutical ingredients and confirmation of safety to promote the research program adopted by the Special District for Development of Advanced Medical Care (super special district).

The anti-cancer drug for which GenomIdea and TSD Japan, Inc. ("TSD") entered into a basic agreement on October 9, 2008, in preparation for signing a licensing contract (GEN0101/TSD-0014), that uses the regulation of cancer immunity. The development of this drug is one of the programs for the development of drugs to enhance immunity in the Projects for the Development of Cutting-Edge Immunity Drugs and the Development of Innovative Technology of Cutting-Edge Antibody Drugs and Adjuvants adopted by the Special District for Development of Advanced Medical Care (super special district) on November 18, 2008. GenomIdea is currently participating in this program as a bio-venture

company, working in collaboration with Professor Yasufumi Kaneda from the Osaka University Graduate School of Medicine.

A program adopted by a super special district can obtain support from the regulatory authorities, including the Ministry of Health, Labor and Welfare and the Pharmaceuticals and Medical Devices Agency. The support includes pharmaceutical consultation from the early development stage as well as quicker and better-quality review for approval. Drugs and medical devices that are considered to be in particular demand are given priority in consultation and review. GenomIdea is developing an anti-cancer drug, GEN0101/TSD-0014, in collaboration with Osaka University Graduate School of Medicine and TSD. By taking advantage of the benefits that the program enjoys by being adopted under a super special district, the company is striving to find a practical application for GEN0101/TSD-0014 as quickly as possible.

The project adopted by the super special district targets the development of anti-cancer drugs that regulate immunity. GenomIdea has established formulation technology, manufactured active pharmaceutical ingredient and confirmed safety, which are essential for clinical studies.

The manufacture of cutting-edge biotechnology-based drugs using cultured cells that are also adopted in the manufacture of antibody drugs requires a detailed evaluation of conditions to ensure that manufacturing efficiency is improved and stabilized. Achieving this objective requires that a special cell

bank (master cell bank) be established and that manufacture be strictly controlled using a bioreactor system. It also requires that manufacturing data be acquired so that a specification can be set for active pharmaceutical ingredient and their formulation through the experimental manufacture of several or several dozens of batches on a manufacturing scale for clinical studies. In this project, GenomIdea has improved manufacturing stability and has acquired data for setting a specification for manufacturing by manufacturing active pharmaceutical ingredient at the GLP level for preclinical studies (confirmation of safety through animal studies), using its established manufacturing technology. GenomIdea has also been evaluating the formulation technology necessary for the clinical development of GEN0101/TSD-0014, and has established stabilization technology using freeze-drying technology.

GenomIdea will now work in collaboration with TSD and strive to facilitate the immediate start of clinical studies, taking advantage of the benefits of being a super special district, and conduct meetings with the regulatory authorities.